MGZ 0.00% 2.0¢ medigard limited

The Blood Collection Device now has granted patents in...

  1. 7,517 Posts.
    lightbulb Created with Sketch. 845
    The Blood Collection Device now has granted patents in Australia, United States, Japan, Canada and Europe with the patent being validated in twenty six European countries.

    http://www.medigard.com.au/products-blood-collection-device

    The 3ml vacuum retractable syringe has granted patents in South Africa, United States, Australia, China Japan and Canada while the 1ml syringe has patents granted in South Africa, China, Australia, United States and Japan.

    http://www.medigard.com.au/products-auto-retractable-syringe

    The Blood Flash Needle which will be the next focus for the Company and Sol Millennium has granted patents in Australia, South Africa and Europe.

    http://www.medigard.com.au/products-flash-back-needle

    __________________________

    Later in the pipeline: http://www.medigard.com.au/products-intravenous-valve

    The Medigard Intravenous Valve operates both as an essential component of the cannula and as a standalone device.
    IV access valves are used extensively where catheters are inserted into the body for an extended period of time. The valves are used as access points in the catheters in preference to a syringe for delivering fluid, administering drugs and taking blood samples. The valve gives needleless access and reduces the risk of needlestick injury.

    The Medigard IV Valve is a two-way valve allowing the introduction of liquids and the withdrawal of blood. It provides clear visibility of fluids. A syringe can be inserted with or without a Luer lock.

    The Medigard IV Valve design eliminates technology design faults that are common with other IV valve devices. The Medigard device incorporates positive flow that prevents backward flow and the possibility of blood clotting.
 
watchlist Created with Sketch. Add MGZ (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.